# FHD-286 in Subjects With Metastatic Uveal Melanoma

> **NCT04879017** · PHASE1 · TERMINATED · sponsor: **Foghorn Therapeutics Inc.** · enrollment: 76 (actual)

## Conditions studied

- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** FHD-286

## Key facts

- **NCT ID:** NCT04879017
- **Lead sponsor:** Foghorn Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-11
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 76 (ACTUAL)
- **Why stopped:** Sponsor terminated the study for business reasons.
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04879017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04879017, "FHD-286 in Subjects With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04879017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*